MediPharm will supply Cronos with about $30 million of high-quality private label cannabis concentrate over the next 18 months. Cronos will also use MediPharm Labs' extraction facility in Ontario to fulfill certain processing needs under a separate agreement. "As the industry develops and matures, we see opportunity to work with companies like MediPharm Labs that provide specialized, high-quality services and inputs for our products," said Mike Gorenstein, CEO of Cronos Group.